DDInter1622 DDInter1840
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Rosuvastatin {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Rosuvastatin {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Rosuvastatin {u} (Compound) downregulates {v} (Gene) CCND1
CCND1 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Rosuvastatin {u} may lead to a major life threatening interaction when taken with {v} Gemfibrozil
Gemfibrozil {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Rosuvastatin {u} may lead to a major life threatening interaction when taken with {v} Gemfibrozil
Gemfibrozil {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Rosuvastatin {u} (Compound) downregulates {v} (Gene) CCL2
CCL2 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Rosuvastatin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Rosuvastatin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Rosuvastatin (Compound) downregulates CCND1 (Gene) and CCND1 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Rosuvastatin may lead to a major life threatening interaction when taken with Gemfibrozil and Gemfibrozil (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Rosuvastatin may lead to a major life threatening interaction when taken with Gemfibrozil and Gemfibrozil (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Rosuvastatin (Compound) downregulates CCL2 (Gene) and CCL2 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)